查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1930110

全球心臟生物标记市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的考量因素以及未来预测（2026-2034）

Cardiac Biomarkers Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 135 Pages | 商品交期: 请询问到货日

价格

心臟生物标记市场成长驱动因素

全球心臟生物标记市场在心血管疾病 (CVD) 的早期诊断和管理中发挥着至关重要的作用。心臟生物标记是内源性物质，例如酵素、荷尔蒙和蛋白质，它们在异常心臟事件期间释放到血液中。 这些生物标记有助于医疗专业人员诊断危及生命的疾病，例如心肌梗塞、急性冠状动脉综合征 (ACS) 和充血性心臟衰竭。

根据 Fortune Business Insights 的数据显示，2025 年全球心臟生物标记市场价值为 209 亿美元。预计到 2026 年，该市场将成长至 234.5 亿美元，到 2034 年将达到 602.9 亿美元，2026 年至 2034 年的复合年增长率 (CAGR) 为 12.53%。这一强劲的成长前景得益于心血管疾病盛行率的上升、技术的进步以及快速诊断测试的日益普及。

市场规模与关键指标

  • 市场规模（2025年）：209亿美元
  • 市场规模（2026年）：234.5亿美元
  • 市场规模（2034年）：602.9亿美元
  • 复合年增长率（2026-2034年）：12.53%
  • 主要地区（2025年）：北美（市占率：38.94%）

北美地区凭藉其先进的医疗保健基础设施、心血管疾病高发病率以及对创新生物标记检测技术的早期应用，在2025年占了市场主导地位。

市场趋势

影响心臟生物标记市场的最显着趋势之一是即时检测（POC​​）生物标记检测的日益普及。 与传统的实验室检测相比，即时检测 (POC) 可显着缩短诊断时间。例如，罗氏的 Elexis Troponin T Gen 5 Stat 检测可在约 9 分钟内提供结果，从而提高急救效率。此趋势在已开发经济体和新兴经济体中均呈现上升趋势。

市场驱动因素

心血管疾病盛行率的上升是市场成长的主要驱动因素。吸烟、肥胖、糖尿病和缺乏运动等生活方式因素加剧了全球心臟病负担。此外，新冠肺炎疫情凸显了先前患有心血管疾病患者的脆弱性。研究表明，新冠肺炎患者发生心肌损伤、心肌炎和心臟衰竭的风险更高，这显着增加了疫情期间对心臟生物标记检测的需求。

另一个关键驱动因素是新型高灵敏度生物标记检测的推出。 西门子和雅培等公司推出的先进肌钙蛋白检测方法获得监管部门批准，提高了心臟事件的早期准确检测率，进一步推动了市场普及。

市场限制因子

儘管成长前景强劲，但挑战包括即时检测试剂盒供应有限以及实验室检测週期长。某些生物标誌物，例如 CK-MB，在症状出现数小时后才能检测到，这可能会延迟诊断和治疗，尤其是在紧急情况下。

细分市场分析

依适应症划分，市场可分为心肌梗塞、充血性心臟衰竭、急性冠状动脉综合症和其他。 受全球急性冠状动脉综合症发病率上升的推动，急性冠状动脉综合症细分市场预计将在2026年占主导地位，市场占有率达55.74%。

依生物标记类型划分，肌钙蛋白预计将占最大的市场占有率，达50.26%，这主要归功于其高特异性以及在心肌梗塞和急性冠脉综合征诊断中的广泛应用。其他细分市场包括肌酸激酶、脑钠肽（BNP）和肌红蛋白。

依终端用户划分，医院预计将在2026年占主导地位，市占率达52.32%。这主要得益于住院患者数量的增加、发展中国家基础设施的不断完善以及有利的报销政策。

区域分析

  • 北美：该市场仍是领先区域，预计到 2025 年将达到 81.4 亿美元。
  • 欧洲：预计成长强劲，主要受心肌梗塞和急性冠状动脉综合症 (ACS) 病例增加的推动。
  • 亚太地区：由于医疗基础设施的扩张以及中国、印度和日本等国家/地区应用率的提高，预计亚太地区将以显着的复合年增长率增长。
  • 拉丁美洲、中东和非洲：由于认知度低和技术应用缓慢，预期成长较为温和。

产业主要参与者

在全球心臟生物标记市场运作的主要公司包括：罗氏 (F. Hoffmann-La Roche)、雅培 (Abbott)、西门子 (Siemens)、贝克曼库尔特 (Beckman Coulter)、Bio-Rad Laboratories、赛默飞世尔科技 (Thermo Fisher Sciificbio) 和生物梅里埃 (Mérieux)。 这些公司正专注于创新、产品发布和监管审批，以巩固其市场地位。

市场规模单位：价值（十亿美元）

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇

第四章：关键考虑因素

  • 主要地区和国家心血管疾病盛行率（2025 年）
  • COVID-19 对体外诊断市场的影响概述
  • 主要公司新产品发布
  • 主要趋势：併购等
  • 已采取的主要措施企业和政府如何克服 COVID-19 的影响
  • 摘要：COVID-19 对心臟检测的影响

第五章：全球心臟生物标记市场分析：洞察与预测（2021-2034）

  • 主要分析/摘要
  • 市场分析、洞察与预测：依适应症划分
    • 心肌梗塞
    • 充血性心臟衰竭
    • 急性冠状动脉综合症
    • 其他
  • 市场分析、洞察与预测：依生物标记划分
    • 肌钙蛋白
    • 肌酸激酶-MB (CK-MB)
    • B型钠尿肽 (BNP)
    • 肌红蛋白
    • 其他
  • 市场分析，洞察与预测：依最终用户划分
    • 医院
    • 专科诊所
  • 市场分析、洞察与预测：依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美心臟生物标记市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章 欧洲心臟生物标记市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国王国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章 亚太地区心臟生物标记市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章 拉丁美洲心臟生物标记市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区美国

第十章：中东与非洲心臟生物标记市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 海湾合作委员会 (GCC) 国家
    • 南非
    • 中东和非洲其他地区

第11章 竞争分析

  • 主要的产业趋势
  • 世界市场占有率分析(2021年)
  • 企业简介
  • F. Hoffmann-La Roche AG
  • Abbott
  • Siemens AG
  • Creative Diagnostics
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc.
  • Thermo Fisher Scientific Inc.
  • bioMerieux SA
  • Other Prominent Players

第12章 策略性建议

Product Code: FBI101233

Growth Factors of cardiac biomarkers Market

The global cardiac biomarkers market plays a critical role in the early diagnosis and management of cardiovascular diseases (CVDs). Cardiac biomarkers are endogenous substances such as enzymes, hormones, and proteins that are released into the bloodstream during abnormal cardiac events. These biomarkers assist healthcare professionals in diagnosing life-threatening conditions such as myocardial infarction, acute coronary syndrome (ACS), and congestive heart failure.

According to Fortune Business Insights, the global cardiac biomarkers market was valued at USD 20.9 billion in 2025. The market is projected to grow to USD 23.45 billion in 2026 and further reach USD 60.29 billion by 2034, registering a compound annual growth rate (CAGR) of 12.53% during 2026-2034. The strong growth outlook is supported by increasing cardiovascular disease prevalence, technological advancements, and rising adoption of rapid diagnostic tests.

Market Size and Key Metrics

  • 2025 Market Size: USD 20.9 billion
  • 2026 Market Size: USD 23.45 billion
  • 2034 Market Size: USD 60.29 billion
  • CAGR (2026-2034): 12.53%
  • Dominant Region (2025): North America (38.94% market share)

North America dominated the market in 2025 due to advanced healthcare infrastructure, a high incidence of cardiovascular diseases, and early adoption of innovative biomarker testing technologies.

Market Trends

One of the most prominent trends shaping the cardiac biomarkers market is the increasing adoption of point-of-care (POC) biomarker testing. POC tests significantly reduce diagnosis time compared to conventional laboratory-based testing. For instance, Roche's Elecsys Troponin T Gen 5 Stat test provides results in approximately nine minutes, improving emergency care efficiency. This trend is gaining traction in both developed and emerging economies.

Market Drivers

The rising prevalence of cardiovascular diseases is the primary driver of market growth. Lifestyle factors such as smoking, obesity, diabetes, and physical inactivity are contributing to the increasing burden of heart diseases globally. Additionally, the COVID-19 pandemic highlighted the vulnerability of patients with pre-existing cardiovascular conditions. Studies showed higher risks of myocardial injury, myocarditis, and heart failure among COVID-19 patients, which significantly increased demand for cardiac biomarker testing during the pandemic period.

Another key driver is the introduction of novel and high-sensitivity biomarker tests. Regulatory approvals for advanced troponin assays from companies such as Siemens and Abbott have improved early and accurate detection of cardiac events, further boosting market adoption.

Market Restraints

Despite strong growth prospects, the market faces challenges such as limited availability of point-of-care testing kits and delayed test results from laboratory-based methods. Some biomarkers, including CK-MB, require several hours post-symptom onset to be detectable, which can delay diagnosis and treatment, particularly in emergency settings.

Segmentation Analysis

By Indication, the market is segmented into myocardial infarction, congestive heart failure, acute coronary syndrome, and others. The acute coronary syndrome segment dominated with a 55.74% share in 2026, driven by the rising incidence of ACS globally.

By Biomarker Type, troponin held the largest share at 50.26% in 2026, owing to its high specificity and widespread use in diagnosing myocardial infarction and ACS. Other segments include creatine kinase, BNP, myoglobin, and others.

By End User, hospitals dominated the market with a 52.32% share in 2026, supported by increasing hospital admissions, expanding infrastructure in developing countries, and favorable reimbursement policies.

Regional Analysis

  • North America: Market size reached USD 8.14 billion in 2025 and remains the leading region.
  • Europe: Strong growth driven by increasing myocardial infarction and ACS cases.
  • Asia Pacific: Expected to grow at a significant CAGR due to expanding healthcare infrastructure and rising adoption in China, India, and Japan.
  • Latin America & Middle East & Africa: Moderate growth due to limited awareness and slower technology adoption.

Key Industry Players

Major players operating in the global cardiac biomarkers market include F. Hoffmann-La Roche AG, Abbott, Siemens AG, Beckman Coulter, Bio-Rad Laboratories, Thermo Fisher Scientific, and bioMerieux SA. These companies focus on innovation, product launches, and regulatory approvals to strengthen their market positions.

Conclusion

In conclusion, the global cardiac biomarkers market is poised for robust growth from 2025 to 2034, driven by the increasing prevalence of cardiovascular diseases, technological advancements, and rising demand for rapid diagnostic solutions. With the market expected to grow from USD 20.9 billion in 2025 to USD 60.29 billion by 2034, cardiac biomarkers will remain a cornerstone of modern cardiovascular diagnostics. Continued innovation, improved accessibility of point-of-care testing, and expanding healthcare infrastructure-particularly in emerging economies-will play a crucial role in shaping the future of this market.

Unit Value (USD billion)

Segmentation By Indication

  • Myocardial Infarction
  • Congestive Heart Failure
  • Acute Coronary Syndrome
  • Others

By Biomarker

  • Troponin
  • Creatine Kinase-MB (CK-MB)
  • B-type Natriuretic Peptide (BNP)
  • Myoglobin
  • Others

By End User

  • Hospitals
  • Specialty Clinics

By Geography

  • North America (the U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)
  • Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia- Pacific)
  • Latin America (Brazil, Mexico, and the Rest of Latin America)
  • The Middle East & Africa (South Africa, GCC and the Rest of Middle East & Africa)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities

4. Key Insights

  • 4.1. Prevalence of Cardiovascular Disorders, By Key Regions/ Key Countries, 2025
  • 4.2. Overview of Impact of COVID-19 on the In-vitro Diagnostics Market
  • 4.3. New Product Launches, By Key Market Players
  • 4.4. Key Industry Developments such as Mergers and Acquisitions
  • 4.5. Key Steps Taken by Companies, Government, etc. to Navigate the Impact of Covid-19
  • 4.6. Overview: Impact of Covid-19 on Cardiac Tests

5. Global Cardiac Biomarkers Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Key Findings / Summary
  • 5.2. Market Analysis, Insights and Forecast - By Indication
    • 5.2.1. Myocardial Infarction
    • 5.2.2. Congestive Heart Failure
    • 5.2.3. Acute Coronary Syndrome
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Biomarkers
    • 5.3.1. Troponin
    • 5.3.2. Creatine kinase-MB (CK-MB)
    • 5.3.3. B-type natriuretic peptide (BNP)
    • 5.3.4. Myoglobin
    • 5.3.5. Others
  • 5.4. Market Analysis, Insights and Forecast - By End User
    • 5.4.1. Hospitals
    • 5.4.2. Speciality Clinics
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Cardiac Biomarkers Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Key Findings / Summary
  • 6.2. Market Analysis, Insights and Forecast - By Indication
    • 6.2.1. Myocardial Infarction
    • 6.2.2. Congestive Heart Failure
    • 6.2.3. Acute Coronary Syndrome
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Biomarkers
    • 6.3.1. Troponin
    • 6.3.2. Creatine kinase-MB (CK-MB)
    • 6.3.3. B-type natriuretic peptide (BNP)
    • 6.3.4. Myoglobin
    • 6.3.5. Others
  • 6.4. Market Analysis, Insights and Forecast - By End User
    • 6.4.1. Hospitals
    • 6.4.2. Speciality Clinics
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Cardiac Biomarkers Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Key Findings / Summary
  • 7.2. Market Analysis, Insights and Forecast - By Indication
    • 7.2.1. Myocardial Infarction
    • 7.2.2. Congestive Heart Failure
    • 7.2.3. Acute Coronary Syndrome
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Biomarkers
    • 7.3.1. Troponin
    • 7.3.2. Creatine kinase-MB (CK-MB)
    • 7.3.3. B-type natriuretic peptide (BNP)
    • 7.3.4. Myoglobin
    • 7.3.5. Others
  • 7.4. Market Analysis, Insights and Forecast - By End User
    • 7.4.1. Hospitals
    • 7.4.2. Speciality Clinics
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Spain
    • 7.5.5. Italy
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Cardiac Biomarkers Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Key Findings / Summary
  • 8.2. Market Analysis, Insights and Forecast - By Indication
    • 8.2.1. Myocardial Infarction
    • 8.2.2. Congestive Heart Failure
    • 8.2.3. Acute Coronary Syndrome
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Biomarkers
    • 8.3.1. Troponin
    • 8.3.2. Creatine kinase-MB (CK-MB)
    • 8.3.3. B-type natriuretic peptide (BNP)
    • 8.3.4. Myoglobin
    • 8.3.5. Others
  • 8.4. Market Analysis, Insights and Forecast - By End User
    • 8.4.1. Hospitals
    • 8.4.2. Speciality Clinics
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 8.5.1. Japan
    • 8.5.2. China
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Cardiac Biomarkers Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Key Findings / Summary
  • 9.2. Market Analysis, Insights and Forecast - By Indication
    • 9.2.1. Myocardial Infarction
    • 9.2.2. Congestive Heart Failure
    • 9.2.3. Acute Coronary Syndrome
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Biomarkers
    • 9.3.1. Troponin
    • 9.3.2. Creatine kinase-MB (CK-MB)
    • 9.3.3. B-type natriuretic peptide (BNP)
    • 9.3.4. Myoglobin
    • 9.3.5. Others
  • 9.4. Market Analysis, Insights and Forecast - By End User
    • 9.4.1. Hospitals
    • 9.4.2. Speciality Clinics
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Cardiac Biomarkers Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Key Findings / Summary
  • 10.2. Market Analysis, Insights and Forecast - By Indication
    • 10.2.1. Myocardial Infarction
    • 10.2.2. Congestive Heart Failure
    • 10.2.3. Acute Coronary Syndrome
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Biomarkers
    • 10.3.1. Troponin
    • 10.3.2. Creatine kinase-MB (CK-MB)
    • 10.3.3. B-type natriuretic peptide (BNP)
    • 10.3.4. Myoglobin
    • 10.3.5. Others
  • 10.4. Market Analysis, Insights and Forecast - By End User
    • 10.4.1. Hospitals
    • 10.4.2. Speciality Clinics
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 10.5.1. GCC Countries
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Key Industry Developments
  • 11.2. Global Market Share Analysis (2021)
  • 11.3. Company Profiles (Overview, Products, SWOT, Recent Developments, Strategies, and Financials (based on availability))
    • 11.3.1. F. Hoffmann-La Roche AG
      • 11.3.1.1. Overview,
      • 11.3.1.2. Products,
      • 11.3.1.3. SWOT,
      • 11.3.1.4. Recent Developments,
      • 11.3.1.5. Strategies,
      • 11.3.1.6. Financials (based on availability)
    • 11.3.2. Abbott
      • 11.3.2.1. Overview,
      • 11.3.2.2. Products,
      • 11.3.2.3. SWOT,
      • 11.3.2.4. Recent Developments,
      • 11.3.2.5. Strategies,
      • 11.3.2.6. Financials (based on availability)
    • 11.3.3. Siemens AG
      • 11.3.3.1. Overview,
      • 11.3.3.2. Products,
      • 11.3.3.3. SWOT,
      • 11.3.3.4. Recent Developments,
      • 11.3.3.5. Strategies,
      • 11.3.3.6. Financials (based on availability)
    • 11.3.4. Creative Diagnostics
      • 11.3.4.1. Overview,
      • 11.3.4.2. Products,
      • 11.3.4.3. SWOT,
      • 11.3.4.4. Recent Developments,
      • 11.3.4.5. Strategies,
      • 11.3.4.6. Financials (based on availability)
    • 11.3.5. Beckman Coulter, Inc.
      • 11.3.5.1. Overview,
      • 11.3.5.2. Products,
      • 11.3.5.3. SWOT,
      • 11.3.5.4. Recent Developments,
      • 11.3.5.5. Strategies,
      • 11.3.5.6. Financials (based on availability)
    • 11.3.6. Bio-Rad Laboratories, Inc.
      • 11.3.6.1. Overview,
      • 11.3.6.2. Products,
      • 11.3.6.3. SWOT,
      • 11.3.6.4. Recent Developments,
      • 11.3.6.5. Strategies,
      • 11.3.6.6. Financials (based on availability)
    • 11.3.7. Thermo Fisher Scientific Inc.
      • 11.3.7.1. Overview,
      • 11.3.7.2. Products,
      • 11.3.7.3. SWOT,
      • 11.3.7.4. Recent Developments,
      • 11.3.7.5. Strategies,
      • 11.3.7.6. Financials (based on availability)
    • 11.3.8. bioMerieux SA
      • 11.3.8.1. Overview,
      • 11.3.8.2. Products,
      • 11.3.8.3. SWOT,
      • 11.3.8.4. Recent Developments,
      • 11.3.8.5. Strategies,
      • 11.3.8.6. Financials (based on availability)
    • 11.3.9. Other Prominent Players
      • 11.3.9.1. Overview,
      • 11.3.9.2. Products,
      • 11.3.9.3. SWOT,
      • 11.3.9.4. Recent Developments,
      • 11.3.9.5. Strategies,
      • 11.3.9.6. Financials (based on availability)

12. Strategic Recommendations

List of Tables

  • Table 1: Global Cardiac Biomarkers Market Revenue (USD Bn) Forecast, by Indication, 2021-2034
  • Table 2: Global Cardiac Biomarkers Market Revenue (USD Bn) Forecast, by Biomarker, 2021-2034
  • Table 3: Global Cardiac Biomarkers Market Revenue (USD Bn) Forecast, by End User, 2021-2034
  • Table 4: Global Cardiac Biomarkers Market Revenue (USD Bn) Forecast, by Region, 2021-2034
  • Table 5: North America Cardiac Biomarkers Market Revenue (USD Bn) Forecast, by Indication, 2021-2034
  • Table 6: North America Cardiac Biomarkers Market Revenue (USD Bn) Forecast, by Biomarker, 2021-2034
  • Table 7: North America Cardiac Biomarkers Market Revenue (USD Bn) Forecast, by End User, 2021-2034
  • Table 8: North America Cardiac Biomarkers Market Revenue (USD Bn) Forecast, By Country, 2021-2034
  • Table 9: Europe Cardiac Biomarkers Market Revenue (USD Bn) Forecast, by Indication, 2021-2034
  • Table 10: Europe Cardiac Biomarkers Market Revenue (USD Bn) Forecast, by Biomarker, 2021-2034
  • Table 11: Europe Cardiac Biomarkers Market Revenue (USD Bn) Forecast, by End User, 2021-2034
  • Table 12: Europe Cardiac Biomarkers Market Revenue (USD Bn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Cardiac Biomarkers Market Revenue (USD Bn) Forecast, by Indication, 2021-2034
  • Table 14: Asia Pacific Cardiac Biomarkers Market Revenue (USD Bn) Forecast, by Biomarker, 2021-2034
  • Table 15: Asia Pacific Cardiac Biomarkers Market Revenue (USD Bn) Forecast, by End User, 2021-2034
  • Table 16: Asia Pacific Cardiac Biomarkers Market Revenue (USD Bn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America Cardiac Biomarkers Market Revenue (USD Bn) Forecast, by Indication, 2021-2034
  • Table 18: Latin America Cardiac Biomarkers Market Revenue (USD Bn) Forecast, by Biomarker, 2021-2034
  • Table 19: Latin America Cardiac Biomarkers Market Revenue (USD Bn) Forecast, by End User, 2021-2034
  • Table 20: Latin America Cardiac Biomarkers Market Revenue (USD Bn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Cardiac Biomarkers Market Revenue (USD Bn) Forecast, by Indication, 2021-2034
  • Table 22: Middle East & Africa Cardiac Biomarkers Market Revenue (USD Bn) Forecast, by Biomarker, 2021-2034
  • Table 23: Middle East & Africa Cardiac Biomarkers Market Revenue (USD Bn) Forecast, by End User, 2021-2034
  • Table 24: Middle East & Africa Cardiac Biomarkers Market Revenue (USD Bn) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Cardiac Biomarkers Market Revenue Breakdown (USD Bn, %) by Region, 2025& 2034
  • Figure 2: Global Cardiac Biomarkers Market Value Share (%), by Indication, 2025& 2034
  • Figure 3: Global Cardiac Biomarkers Market Forecast (USD Bn), by Myocardial Infarction, 2021-2034
  • Figure 4: Global Cardiac Biomarkers Market Forecast (USD Bn), by Congestive Heart Failure, 2021-2034
  • Figure 5: Global Cardiac Biomarkers Market Forecast (USD Bn), by Acute Coronary Syndrome, 2021-2034
  • Figure 6: Global Cardiac Biomarkers Market Forecast (USD Bn), by Others, 2021-2034
  • Figure 7: Global Cardiac Biomarkers Market Value Share (%), by Biomarker, 2025& 2034
  • Figure 8: Global Cardiac Biomarkers Market Forecast (USD Bn), by Troponin, 2021-2034
  • Figure 9: Global Cardiac Biomarkers Market Forecast (USD Bn), by Creatine kinase-MB (CK-MB), 2021-2034
  • Figure 10: Global Cardiac Biomarkers Market Forecast (USD Bn), by B-type natriuretic peptide (BNP), 2021-2034
  • Figure 11: Global Cardiac Biomarkers Market Forecast (USD Bn), by Myoglobin, 2021-2034
  • Figure 12: Global Cardiac Biomarkers Market Forecast (USD Bn), by Others, 2021-2034
  • Figure 13: Global Cardiac Biomarkers Market Value Share (%), by End User, 2025& 2034
  • Figure 14: Global Cardiac Biomarkers Market Forecast (USD Bn), by Hospitals, 2021-2034
  • Figure 15: Global Cardiac Biomarkers Market Forecast (USD Bn), by Speciality Clinics, 2021-2034
  • Figure 16: Global Cardiac Biomarkers Market Value (USD Bn), by Region, 2025& 2034
  • Figure 17: North America Cardiac Biomarkers Market Value (USD Bn), by Indication, 2025& 2034
  • Figure 18: North America Cardiac Biomarkers Market Value Share (%), by Indication, 2025
  • Figure 19: North America Cardiac Biomarkers Market Value (USD Bn), by Biomarker, 2025& 2034
  • Figure 20: North America Cardiac Biomarkers Market Value Share (%), by Biomarker, 2025
  • Figure 21: North America Cardiac Biomarkers Market Value (USD Bn), by End User, 2025& 2034
  • Figure 22: North America Cardiac Biomarkers Market Value Share (%), by End User, 2025
  • Figure 23: North America Cardiac Biomarkers Market Value (USD Bn), By Country, 2025& 2034
  • Figure 24: North America Cardiac Biomarkers Market Value Share (%), By Country, 2025
  • Figure 25: Europe Cardiac Biomarkers Market Value (USD Bn), by Indication, 2025& 2034
  • Figure 26: Europe Cardiac Biomarkers Market Value Share (%), by Indication, 2025
  • Figure 27: Europe Cardiac Biomarkers Market Value (USD Bn), by Biomarker, 2025& 2034
  • Figure 28: Europe Cardiac Biomarkers Market Value Share (%), by Biomarker, 2025
  • Figure 29: Europe Cardiac Biomarkers Market Value (USD Bn), by End User, 2025& 2034
  • Figure 30: Europe Cardiac Biomarkers Market Value Share (%), by End User, 2025
  • Figure 31: Europe Cardiac Biomarkers Market Value (USD Bn), By Country/ Sub-region, 2025& 2034
  • Figure 32: Europe Cardiac Biomarkers Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 33: Asia Pacific Cardiac Biomarkers Market Value (USD Bn), by Indication, 2025& 2034
  • Figure 34: Asia Pacific Cardiac Biomarkers Market Value Share (%), by Indication, 2025
  • Figure 35: Asia Pacific Cardiac Biomarkers Market Value (USD Bn), by Biomarker, 2025& 2034
  • Figure 36: Asia Pacific Cardiac Biomarkers Market Value Share (%), by Biomarker, 2025
  • Figure 37: Asia Pacific Cardiac Biomarkers Market Value (USD Bn), by End User, 2025& 2034
  • Figure 38: Asia Pacific Cardiac Biomarkers Market Value Share (%), by End User, 2025
  • Figure 39: Asia Pacific Cardiac Biomarkers Market Value (USD Bn), By Country/ Sub-region, 2025& 2034
  • Figure 40: Asia Pacific Cardiac Biomarkers Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 41: Latin America Cardiac Biomarkers Market Value (USD Bn), by Indication, 2025& 2034
  • Figure 42: Latin America Cardiac Biomarkers Market Value Share (%), by Indication, 2025
  • Figure 43: Latin America Cardiac Biomarkers Market Value (USD Bn), by Biomarker, 2025& 2034
  • Figure 44: Latin America Cardiac Biomarkers Market Value Share (%), by Biomarker, 2025
  • Figure 45: Latin America Cardiac Biomarkers Market Value (USD Bn), by End User, 2025& 2034
  • Figure 46: Latin America Cardiac Biomarkers Market Value Share (%), by End User, 2025
  • Figure 47: Latin America Cardiac Biomarkers Market Value (USD Bn), By Country/ Sub-region, 2025& 2034
  • Figure 48: Latin America Cardiac Biomarkers Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 49: Middle East & Africa Cardiac Biomarkers Market Value (USD Bn), by Indication, 2025& 2034
  • Figure 50: Middle East & Africa Cardiac Biomarkers Market Value Share (%), by Indication, 2025
  • Figure 51: Middle East & Africa Cardiac Biomarkers Market Value (USD Bn), by Biomarker, 2025& 2034
  • Figure 52: Middle East & Africa Cardiac Biomarkers Market Value Share (%), by Biomarker, 2025
  • Figure 53: Middle East & Africa Cardiac Biomarkers Market Value (USD Bn), by End User, 2025& 2034
  • Figure 54: Middle East & Africa Cardiac Biomarkers Market Value Share (%), by End User, 2025
  • Figure 55: Middle East & Africa Cardiac Biomarkers Market Value (USD Bn), By Country/ Sub-region, 2025& 2034
  • Figure 56: Middle East & Africa Cardiac Biomarkers Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 57: Global Cardiac Biomarkers Market Share (%), By Company, 2025